PFE · 8-K · 20260804PR000094
Geographic Market Commentary
PFIZER INC · 2026-08-04 · Importance 10 · Surprise 6 · Contradicted
Eliquis delivered global growth, with higher U.S. net price and demand partly offset by generic entry and price erosion in some international markets. Vyndaqel’s international performance benefited from strong demand, increased diagnosis and improved access, while U.S. growth faced price erosion from new payer contracts. Lorbrena increased patient share in the U.S., China and selected other international markets. COVID-19 demand declined across both U.S. and international markets, with lower government purchases additionally affecting Paxlovid internationally.
Key facts
- Total U.S. revenues for Second-Quarter 2026: $8,857 million, unchanged versus prior period (—) source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | unclear | realized | 0.0% | Total U.S. revenues for Second-Quarter 2026: $8,857 million, unchanged versus prior period (—) |